CRISPR‐mediated knockout of FSP1 in tumor cells not only enhances ferroptosis susceptibility but also activates DCs through DAMP release, improving anti‐PD‐1 immunotherapy response rates [681]. This evidence concerns the gene AIFM2 and neoplasm.